Alto Neuroscience (NYSE:ANRO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Alto Neuroscience (NYSE:ANRO) from a strong sell rating to a sell rating in a research report sent to investors on Saturday morning.

A number of other research firms have also recently issued reports on ANRO. HC Wainwright reiterated a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. BTIG Research increased their price objective on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. Robert W. Baird cut their price objective on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Finally, Zacks Research lowered shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 22nd. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.25.

Alto Neuroscience Stock Up 4.9%

Shares of Alto Neuroscience stock opened at $33.70 on Friday. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -13.93 and a beta of 1.06. Alto Neuroscience has a twelve month low of $3.05 and a twelve month high of $34.35. The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07. The business’s 50 day simple moving average is $26.28 and its 200-day simple moving average is $22.91.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.08. Equities research analysts forecast that Alto Neuroscience will post -3 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Commodore Capital LP raised its holdings in Alto Neuroscience by 49.4% during the first quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock worth $61,217,000 after purchasing an additional 900,000 shares in the last quarter. Vestal Point Capital LP boosted its stake in Alto Neuroscience by 161.6% during the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after purchasing an additional 1,535,000 shares in the last quarter. Perceptive Advisors LLC boosted its stake in Alto Neuroscience by 12.6% during the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after purchasing an additional 225,500 shares in the last quarter. Armistice Capital LLC increased its position in shares of Alto Neuroscience by 0.7% during the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock valued at $6,577,000 after purchasing an additional 12,000 shares during the period. Finally, Spruce Street Capital LP increased its position in shares of Alto Neuroscience by 494.7% during the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after purchasing an additional 1,102,366 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.